CAPLIPOINTCaplin Point Laboratories Limited Forensic Risk Analysis

Pharmaceuticals
Risk ClassStable
Market Cap₹12,771 Cr
Primary DriverBalance Sheet Stress
Flagium AI Risk Score
Stable structural profile. Financial profile appears resilient.
8 / 100
-2 QoQ
Improving
Sentinel Insight

Financial profile remains stable for now. Pressure is receding in balance sheet stress. This indicates that forensic pressure is currently receding. Minor improvements are visible in the risk trend.

19.2th %ile (Sector)Accel: +0 Qtrs
Updated2026-06-02
Market View
₹1,988.1▼0.54%
PeriodQ4 FY26

Score Waterfall
Absolute contribution points of each forensic pillar to the final risk score. Derived from: Sector Baseline + Active Penalties - Mitigation Buffers.

Balance Sheet Stress
+8.0 pts
Final Composite Risk8 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 5 → 8 over 13 quarters.

Expected Direction
⚠ Watch
Primary Deterioration Drivers
  • Relative Growth Weakness
  • Working Capital Expansion
  • Cash Conversion Deficit
What to Watch Next Quarter
  • Operating cash flow
  • Working capital efficiency
  • Operating profit margins

Active Risk Objects (3)

CriticalHigh
Cash Conversion Deficit
📊 Earnings QualityAnnualActive for 3 Years
More Detail
Impact Weight6/15
MomentumPersistent
Last SignalFY2026
CAPLIPOINT: OCF below Net Profit in 3/3 recent years.

"Cash conversion is dangerously low. Operational cash flow is significantly trailing reported PAT."

Working Capital Expansion
💧 Liquidity & CoverageAnnualActive for 2 Years
More Detail
Impact Weight10/15
MomentumAccelerating
Last SignalQ4 FY2026
Working capital expansion detected: Receivable days increased by 9.7%.

"Early signs of working capital expansion. Receivable or inventory days are creeping up."

Relative Growth Weakness
📊 Earnings QualityAnnualActive for 2 Years
More Detail
Impact Weight12/15
MomentumAccelerating
Last SignalQ3 FY2026
Revenue growth consistently lags behind sector median (12.8%).

"Early signs of earnings quality decay. Profitability is being driven by non-core items."

Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Resilience Matrix
Diagnostic benchmarking comparing structural sensitivity and risk buffers against sector medians.
MetricValuevs SectorSignal
Volatility (σ)2.257.70✅ RESILIENT
Sensitivity (ε_s)11.00✅ RESILIENT
Escalation Prob.5%5%✅ NEUTRAL
Safety Buffer+58.0+47.0✅ RESILIENT
Forensic Benchmark Context: Pharmaceuticals (n=99 peers)

Correlation Analysis
Visualizing the relationship between stock price movement and structural risk objects.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
₹1,988.1(-0.54%)
1M Divergence+14.06%
1 Week-2.34%
1 Month+16.33%
6 Months+0.61%
1 Year-7.83%
2 Year+54.7%
3 Year+163.95%
Sector Average (1M)+2.27%
Sentinel Forensic Assessment
ALGORITHMIC RISK PROFILE • NON-ADVISORY

The structural architecture is currently robust. Capital resilience buffers in balance sheet stress remain well-maintained against forensic benchmarks. Systematic scans of core structural metrics confirm the absence of material structural stress. The current structural trajectory supports a stable risk outlook.

CAPLIPOINT • MARKET STRUCTURE

Stage 1 — Accumulation

The company is in a foundational phase. Risk metrics are stabilizing as the company builds a base for potential future fundamental improvement.

Stage Transition Prob.20%
Trend QualityEarly Base
Phase Progression
Phase Progression Score40%
Readiness LabelLow (Early Base Consolidation)
Probability of Advancing20%
CoinTree Momentum
Composite Z-Score+0.3318σ
Improving momentum strength
Universe Rank
A cross-sectional rank of this stock's composite momentum score compared to all other tracked equities in the universe. A rank of #1 of 1035 means it has the strongest overall price momentum in the market.
#568 of 2716
Top 20.91% in momentum strength
Timeframe Sparklines
1W-2.3%
1M+16.3%
6M+0.6%
Weinstein Indicators
150 DMA₹1,826.6
200 DMA₹1,901.77
150 DMA Slope-0.7769%Declining
Relative Strength+10.68%Leading
Relative Turnover (RTR)1.8961
ParticipationHealthy

PEER COMPARISON

Ranked comparison against sector peers

This company appears relatively stable compared to the Sector Mean (19).
ABBOTINDIAABBOTINDIA
0 Risk
Sector %ile0th
Delta0
Active Flags0
Accel+0
Governance

Stable

CAPLIPOINTCaplin Point Laboratories Limited
8 Risk
Sector %ile19th
Delta-2
Active Flags3
Accel+0
Balance Sheet Stress

Stable

AARTIDRUGSAarti Drugs Limited
19 Risk
Sector %ile51th
Delta-5
Active Flags11
Accel+0
Competitive Position

Stable

AAREYDRUGSAarey Drugs & Pharmaceuticals Limited
23 Risk
Sector %ile63th
Delta-5
Active Flags20
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Risk Profiles

Solvency
10100th %ile
VS Sector Median (8.5)
Governance
10100th %ile
VS Sector Median (8.5)
Earnings Quality
10100th %ile
VS Sector Median (8.5)
Balance Sheet Stress
660th %ile
VS Sector Median (8.5)
Competitive Position
10100th %ile
VS Sector Median (8.5)
Growth Sustainability
10100th %ile
VS Sector Median (8.5)

Deterioration Timeline

2026

Working Capital Expansion

2026

Relative Growth Weakness

2026

Relative Growth Weakness

2026

Cash Conversion Deficit

2025

Cash Conversion Deficit

2024

Working Capital Expansion

2024

Cash Conversion Deficit

Key Financials (INR Cr)

PeriodRevenueNet ProfitOCFDebt
FY20262,3036505231
FY20252,0345414321
FY20241,7614613111
FY20231,5233772723